IMMUNOPRECISE ANTIBODIES LTD. FY24 Q3
Earnings Presentation
March 14, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA
Disclosures
Disclaimer
This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the "Company") securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company's securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company's potential cash generation performance in any way.
Forward Looking Statements
This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company's long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "targeting" and "intend" and statements that an event or result "may", "will", "should", "could", or "might" occur or be achieved and other similar expressions.
Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company's management about the Company's business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.
The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company's business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company's most recent Annual Information Form, which is available under the Company's profile on EDGAR at www.sec.gov.edgarand SEDAR+ at www.sedarplus.cafor additional related risks factors that could materially affect the Company's operations and financial results.
Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise accept as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Antibodies. BioStrand and LENSai are trademarks of BioStrand, | 2 |
BV. Talem is an independently operating subsidiary of ImmunoPrecise Antibodies. Talem is a trademark of Talem Therapeutics LLC. |
Fiscal Year 2024 Q3 Earnings Call
Fiscal Year 2024 Q3 Business Update
ir.ipatherapeutics.com | NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. | 3 |
Fiscal Year 2024 Q3 Earnings Call
Driven by mission and strategy
Strategic performance growth drivers with vision and focus
Core objective over next several years:
Innovation | Operational | Strategic |
Excellence | Development | |
Continue to drive transformation, implementation and execution of mAb research in every facet.
ir.ipatherapeutics.com | NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. | 4 |
Fiscal Year 2024 Q3 Earnings Call
Driven by mission and strategy
Continued performance remains strong
Performance drivers: strategic focus on sales, customer engagement, and operational efficiencies
Q3 2024
20% YOY increase
$6.2M total revenue
Q1
Q2
2024
Q3
2024
Q4
2023
2024
Sustained growth:
Four back-to-back revenue record quarters
ir.ipatherapeutics.com| NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. | 5 |
Fiscal Year 2024 Q3 Earnings Call
Driven by mission and strategy
Steady revenue growth
Strategic expansion: Utrecht
and Victoria sites
Notable growth in Oss facility, scaling to meet client demands
- cell programs, contributing significantly to revenue
Hub of
Biotherapeutic
Intelligence™
Emerging markets growth
Launch of LENSaiTM BioIntelligence Suite with the LENSai epitope binning tool
Expanded outreach for
Talem pipeline portfolio
BioStrand success, early revenue from repeat business with large pharma
Trusted by the best: | Over 600+ biotech and |
19 of top 20 pharma clients | pharma clients |
Client retention sustained success
ir.ipatherapeutics.com| NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand and LENSai are a trademarks of BioStrand, BV. | 6 |
The impact of LENSai Universal Foundation AI Model
Seamless multi-omics data integration
Search
Learn
Cluster
Application areas & value
LENSai Powered by HYFTs - Universal AI Foundation Model
The great biosphere connector
Compare
Identify
Generate
Predict
AI/ML
Unlimited scalability- Flexible, responsive, adaptive, innovative customized data products
Drug and antibody discovery and design: Identify and create new drug compounds
- reducing R&D timelines
Clinical trial optimization: Enhancing patient selection and trial design - for more successful clinical trials
Personalized medicine: Tailoring treatments based on individual health data - improving patient outcomes
Partnering Customizing technology for partner needs - creating expedited value and insights
ir.ipatherapeutics.com | NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. | 7 |
Fiscal Year 2024 Q2 Earnings Call
Fiscal Year 2024 Q3 Financial Update
ir.ipatherapeutics.com | NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. | 8 |
Fiscal Year 2024 Q3 Earnings Call
Year to date $18M revenue, 20% growth
$7.0 M
$6.0 M
$5.0 M
$4.0 M $3.0 M $2.0 M $1.0 M $0.0 M
$5.7 M | $6.2 M | $6.2 M | $5.6 M |
$5.2 M | $5.2 M | $5.2 M | |
$4.7 M $4.6 M | $4.7 M | $4.8 M | |
Q1 | Q2 | Q3 | Q4 |
FY24 FY23 FY22
All values listed in CAD.
ir.ipatherapeutics.com | NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. | 9 |
Fiscal Year 2024 Q3 Earnings Call
Strategically built for growth
Year to date revenue shows on track for record year
$25 M | FY22 BioStrand LENSai acquisition to enable revenue and gross | |||||||
margin growth rates higher than historical wet lab | ||||||||
$19 M | $21 M | $18 M | ||||||
$20 M | ||||||||
$17 M | ||||||||
$15 M | $14 M | |||||||
$11 M | $12 M | $11 M | $12 M | $9 M | ||||
$10 M | ||||||||
$8 M | ||||||||
$5 M | $5 M | $5 M | ||||||
$2 M | ||||||||
$ M | ||||||||
FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | Q3 F24 YTD | ||
Revenue | Gross Profit | |||||||
ir.ipatherapeutics.com | NASDAQ:IPA | ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ImmunoPrecise Antibodies Ltd. published this content on 13 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 March 2024 12:27:15 UTC.
